Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes
Conditions
Brief summary
To investigate the predictive roles of adipokines and hepatokines to detect non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia. To examine the association or effects of clinical and biochemical factors (lab results and medication, etc.) on serum levels of adipokines and hepatokines in certain subjects with non-alcoholic fatty liver disease (NAFLD), diabetes, or dyslipidmia.
Interventions
OTHERserum blood sampling
Sponsors
Yonsei University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. dyslipidemia 1. serum triglyceride≥150mg/dl, or taking medication to lower triglyceride levels (e.g. fibrates, niacin, omega-3, etc.) or 2. serum LDL-C≥100mg/dl, or taking medication to lower LDL-C levels (e.g. statin, ezetimibe, etc.) 2. type 2 diabetes 1. defined according to the ADA guideline (DM definition) or 2. taking any anti-diabetic medications 3. non-alcoholic fatty liver disease (NAFLD) 1. diagnosed as having fatty liver by ultrasonogram or 2. diagnosed as having fatty liver by transient elastogram (Fibroscan) or 3. diagnosed as having fatty liver by abdomina CT scan 4. Normal control 1. should not be included in other groups as above and 2. not taking any medication related to diabetes and dyslipidemia and 3. BMI \<25kg/m2
Exclusion criteria
1. subjects who refused to agree with informed consents 2. subjects with organ-transplantation 3. serum creatinine ≥1.5mg/dl 4. pregnant women 5. liver cancer or pancreatic cancer 6. subjects with chronic hepatitis B or C virus infection 7. for NAFLD group, subjects with excessive alcohol consumption (men: ≥210g of alcohol per week, women: ≥140g of alcohol per week)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| new adipokines | To 8h fasting blood sample | several candidate adipokines and hepatokines to predict diseases will be measured using ELISA |
| new hepatokines | To 8h fasting blood sample | several candidate adipokines and hepatokines to predict diseases will be measured using ELISA |
Countries
South Korea
Contacts
Primary ContactBong Soo Cha, MD
Outcome results
None listed